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Abstract
Background: Monitoring the effect of medication by using
an objective measure would bring new perspectives to the
work with patients suffering from Attention Deficit
Hyperactivity Disorder (ADHD).
Objective: In order to objectify and monitor treatment
efficiency, a Continuous Performance Test (the QB Test)
was used and evaluated in daily clinical practice.
Method: A total of 12 boys aged 8-12 fulfilling diagnostic
criteria for ADHD were tested using the QB Test before
and after intake of methylphenidate.
Findings: One hour after intake of test dose of medicine,
there were significant improvements on numbers of
omissions (p=0.014), reaction time (p=0.038), correct
responses (p=0.031) and activity (p=0.045). Non-
significant improvements in reaction time variability
(p=0.190) and correct non-responses (p=0.764) were
found. Number of guesses and errors of commission were
unchanged after medication.
Conclusions: The QB Test can be used to track effects of
medication, showing greatest improvement in the most
inattentive and hyperactive/impulsive children.
Keywords: ADHD, CPT, QB test, Methylphenidate
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) (DSM-IV
and DSM-5) or Hyperkinetic Disorder (ICD-10) is a
neurodevelopmental psychiatric disorder that causes attention
deficits, hyperactivity, and/or impulsiveness [1,2].
To fulfill diagnostic criteria, the symptom debut must be
before age 7 and persist for more than 6 months. The
symptoms can be present to varying degrees but must impact
the patient’s life in at least two different settings, e.g. school
and home [1-3].
ADHD is the most commonly studied and diagnosed
psychiatric disorder in children and adolescents. It occurs in
3-5% of Danish children, and in 15-20% of the children referred
to Child and Adolescent Psychiatry. ADHD is 4 to 5 times more
common in boys than girls, and in half of the patients it
persists into adulthood [4,5].
According to NICE Guidelines [3], the diagnosis should only
be made by a psychiatrist, pediatrician or other appropriately
qualified healthcare professional. The diagnostic process
requires a full clinical and psychosocial assessment, and
observer reports from different life settings. Information from
parents about developmental and psychiatric history is
important, as well as information from school or kindergarten
teachers.
Rating scales such as the Conner’s rating scale, ADHD-rating
scale (-RS), the Child Behaviour Checklist (CBCL) and the
Strengths and Difficulties Questionnaire (SDQ) are valuable
adjunct tools [3].
First-line treatment for school-aged children with ADHD and
moderate impairment is group-based parent-training
education programmes, behavioural and social therapy.
However, in some cases, this will be insufficient, and the child
will need drug treatment. For children with severe ADHD and
severe impairment, drug treatment is first-line treatment [3].
The recommended first-line drug is methylphenidate, which is
the most frequently used drug for ADHD in Denmark [6,7].
In an attempt to support clinical descriptive diagnostics and
systematic monitoring of treatment, cognitive tests in different
set-ups have been investigated [8-12]. Continuous
Performance Test (CPT) is an overall general category of tests
that can be used in many contexts, including ADHD [13].
A review from 2004 gives a summary of the use of different
cognitive tests (Continuous Performance Test, the Gordon
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Diagnostic System, the Children's Checking Task, Delay of
Gratification Tasks, the Choice-Delay Task, and the Stop Signal
Task (SST) [14].
CPT is able to discriminate ADHD from a control group, but
has a large number of false positive and false negative results.
This indicates that CPT is not sufficient to reliably distinguish
between ADHD and non-ADHD subjects or to differentiate
ADHD from other mental disorders [14].
In a number of studies, methylphenidate is shown to
improve symptoms measured on CPT to the extent that
children with ADHD treated with methylphenidate can
perform nearly as well as a control group [9,12,14-18].
There is ongoing research into CPT and its ability to support
diagnostics, monitoring of symptom severity and evaluation of
medication. In an attempt to assess all three core symptoms of
ADHD, the tracking of movement during tests has come into
focus [4,6,8,10,12,19].
Others have investigated the use of CPT in a virtual setting
or as an online test that can be made in the child’s home or at
school, to create a naturalistic setting [11,17].
The Child and Adolescent Psychiatry Unit in Odense uses a
variant of CPT called the QB Test (Quantitative Behavioural
Test). This is a CPT combined with an activity test, which makes
it possible to establish a picture of the complexity of the
disease [10,19].
The purpose of this study was to investigate the objective
effect on ADHD core symptoms after intake of a test-dose of
methylphenidate. Participants who already fulfill diagnostic
criteria of ADHD were grouped on the basis of parent rating on
ADHD-RS. Change in attention function and activity was
measured by QB Test.
Method
Data used in the study was generated from the QB testing of
13 boys in the Child and Adolescent Psychiatry Outpatient
Clinic in Odense and the ADHD Rating Scale (ADHD-RS)
completed by their parents.
The cases included were boys born in 1999-2003 and
diagnosed with ADHD, all in daily treatment with
methylphenidate. The treatment duration varied from months
to years.
Boys with a diagnose of intellectual disability and other
psychiatric comorbidity were excluded from the study. So were
boys treated with medication other than methylphenidate
because, due to the significantly longer half-life of other active
substances, they would not be able to comply with the
medication fasting that was required in this study.
Prior to this study no new IQ measure were made.
There were 30 boys who met the criteria for participation;
13 of them (and their parents) gave consent to participation.
On the day of the trial, the participants attended with a
parent or caregiver without having taken their usual morning
medication. They all had a medication washout from the day
before.
Prior to the execution of the actual test, a presentation
video was displayed, and the children received some initial
training in the program until they were able to demonstrate
that they understood the three aspects of the test; to sit still,
correct and fast pressing and correct non-pressing.
The QB Test was conducted twice (2×15 min); once without
medication and the other an hour after intake of their usual
morning medication.
During the test, the participants and one of two evaluators
sat in a quiet room in front of a computer, wearing a sensor to
detect activity. No interaction between test-person and
evaluator took place during the test. Evaluators were authors
Merete Dam and Katrine Kolmos.
All participants had already tried the QB Test when
diagnosed, or in connection with drug monitoring. We assume
this will not have affected the outcome since it is not possibly
to improve results by repetition. Test retest studies of QB Test
show high reliability [20].
QB Test
The QB Test is a computer program that can test a person’s
attention, activity level and impulsivity and thus generate an
objective measure of ADHD core symptom severity.
The task of the program is to press a button at a specific
stimulus, and refrain at another. In the course of 15 minutes,
the person is shown 225 targets and 225 non-targets [19].
After completing the test, the QB Test program outlines a
summary of the test person’s score and compares the data to
an age-matched control group.
Inattention:
• Reaction time (RT) is the average of elapsed time from
target presentation to response.
• Variability in reaction time (RT-var) is the fluctuation of
reaction time during the test.
• Errors of omission are the number of non-responses to a
target.
• Correct responses are the number of responses to a target.
• Correct non-responses are when refraining from response
to a non-target [10].
Impulsiveness and hyperactivity:
• Guesses are measured as the number of hits before a test
person is able to identify a target or non-target.
• Errors of commission are the number of responses to a
non-target [6,12,18].
• Activity is measured as the distance a test person moves
his head from baseline. This distance is registered by an
infrared camera and is shown as movement around a
centre of a coordinate (cm2) [10,19].
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ADHD - RS
ADHD-RS is a questionnaire in which parents rate the
presence of 18 symptoms on a Likert scale from "never" (0) to
"very often" (3). ADHD-RS gives information on activity,
inattentiveness and impulsivity [18]. The rating scale is
primarily used to monitor treatment efficiency, but also plays
an important role in the diagnostic process [5,7,9].
Methylphenidate
Methylphenidate is a central nervous system stimulant used
in treatment of ADHD. It blocks the reabsorption of dopamine
and increases the activity in the frontal lobes and basal
ganglia. Initially the dose is titrated from 5 mg twice a day to
the optimal level of up to 1.2-1.5 mg/kg/day that achieves
therapeutic benefits and has minimal side effects.
Duration of effect varies from 3-12 hours due to difference
in release. Half-life is around 2-3 hours. Annual review of drug
dose, benefits, side effects, growth and overall monitoring is
recommended [3] (Table 1).
Table 1 Characteristics of the test sample (N=13).
Min-max Mean (SD)
ADHD-RS inattention 8-19 14.2
ADHD-RD hyperactivity/impulsivity 4-19 13.6
Age 8-12 10.5
Daily dose of Methylphenidate (mg) 20-64 37.6
The participants in this study received varying doses (20-64
mg), but all had had monitoring of their drug treatment within
the last year.
Statistical tests and ethics
All analyses were conducted using SPSS ver. 19. Data from
QB testing prior to and after methylphenidate intake were
compared using the paired t-test. Data was normally
distributed. Statistical significance is defined as p<0.05.
The study is designed as a pilot project with the approval of
the research ethics committee in the Region of Southern
Denmark (Project ID S - 20110093).
Results
13 boys completed the QB Test twice and had their
symptoms rated on the ADHD-RS.
One boy was excluded because of oppositional behaviour
that led to obvious mistakes made on purpose. This was
considered not to reflect the true severity of his symptoms,
and therefore the data from this participant were not included
in any analysis (Table 2).
ADHD-RS is used to find those who are likely or most likely
to be inattentive and/or hyperactive/impulsive. According to
the Danish version for interpretation of ADHD-RS, the cut-off is
a score of 9 or more on a given subscale. Scores between 9
and 13 constitute a grey zone that requires more diagnostics.
A person scoring above 13 is likely to have an attention
and/or hyperactivity/impulsivity deficit (Table 3).
Table 2 Paired sample T-test.
Attention measures N=12 Before Methylphenidate After Methylphenidate T-test
 Mean Min Max Mean Min Max Sig. 2-tailed
RT 467.25 323 694 440.08 305 631 0.038*
RT-var 155.08 112 381 144.17 92 421 0.19
Omission 29.92 2 112 10.58 2 41 0.014*
Correct response 186.58 84 223 204 163 223 0.031*
Correct non-response 177.33 86 221 176.25 65 220 0.764
RT=reaction time, RT-var=Reaction time variability, *=P<0.05
Table 3 Paired sample T-test.
Hyperactivity/impulsiveness N=10 Before Methylphenidate After Methylphenidate T-test
 Mean Min Max Mean Min Max Sig. 2-tailed
Activity 113.6 23 234 73.3 28 162 0.045*
Guesses 21.9 0 71 25.3 0 70 0.475
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Commission errors 42.8 3 123 44.2 5 124 0.684
*=P<0.05
12 participants had an inattention score of 9 or more, and
10 had a hyperactivity/impulsivity score of 9 or more and were
therefore included in the statistical analyses.
Discussion
The findings of this study show significant improvements on
numbers of omission (p=0.014), reaction time (p=0.038) and
correct responses (p= 0.031). This shows that the boys are less
inattentive after intake of methylphenidate. It also indicates
that the participants have increased sustained attention after
medication.
No significant improvements in reaction time variability
(p=0.190) or correct non-responses (p=0.764) were found. This
shows that the participants’ fluctuation in reaction time had
not improved significantly on the QB Test after intake of
methylphenidate. The number of correct non-responses
remained the same before and after intake of
methylphenidate.
In this study, we found improvement in hyperactivity after
intake of methylphenidate. The activity of the participants
decreased from 113 to 73 cm2 p=0.045). The findings showed
no improvement in the parameters reflecting impulsivity. The
number of guesses and errors of commission were unchanged
after medication.
A meta-analytic review from 1996 examined how results
differed on the CPT in a group of children with ADHD with or
without treatment with methylphenidate. The review
concluded that omission and errors of commission were
significantly reduced by 39% and 29% respectively in the group
treated with methylphenidate compared to the group that
received placebo [21].
The cases in this study had significant improvement of
omission but not of errors of commission measured on the QB
Test. This difference in findings may be due to the difference in
study design, or the possibility that the QB Test is insufficient
to assess the effect of methylphenidate on impulsivity.
Zalsmann and Solanto examined whether there was a
difference in medication effect on the different subtypes of
ADHD and found that there was a significant improvement
after treatment with methylphenidate in all three subgroups,
but no significant difference between them [22,23].
In this study we found that both the most inattentive and
hyperactive/impulsive improved significantly on some
outcomes. Similar to Zalsmann and Solanto, this study did not
find the improvements of the two groups to be largely
different.
Heiser et al. discussed the correlation between the dose of
methylphenidate and various CPT parameters. They found that
“micro-events” as a sign of hyperactivity and RT variability as a
sign of inattentiveness were significantly correlated to dose
[4].
In a study from 2012, Gunther et al. found that a long-acting
methylphenidate was as effective as two doses of immediate-
release methylphenidate in reducing inattention and
hyperactivity during the course of the day. Impulsivity was
reduced on immediate-release but not on long-acting
methylphenidate [19].
Like Gunther et al., our study showed significant
improvements on some inattention parameters and
hyperactivity, but not impulsivity. Fluctuation of reaction time
was unchanged before and after methylphenidate.
It is likely that RT variability would have been significantly
improved measured on QB Test if the participants’ dose of
methylphenidate had been adjusted just ahead of testing or if
the participants had been tested at another time during the
day.
Another explanation for the lack of significance in
improvement of RT variability could be that the test is not
suitable for children, simply because they get bored and
unfocused, which makes it impossible to track the effect of
methylphenidate.
In recent years, there has been increased focus on
developing tools for objective evaluation of hyperactivity. A
Danish study by Tabori-Kraft, Sørensen et al. used an infrared
camera comparable to the one used in the QB Test. They
examined whether the OPTAx was able to show effect of
methylphenidate. They found significant improvements of
hyperactivity and impulsivity on all parameters. On
inattentiveness, they found significant improvements of RT
variability, correct pressing and correct non-pressing, but no
improvements of RT or omission [6].
We expected results from the QB Test to point in the same
direction because of the similarity of design and aim. The QB
Test showed the same improvement of hyperactivity, but no
improvements on guesses or errors of commission as an
expression of repression of impulsivity.
Inattentiveness (RT, correct pressing and omissions) was
significantly improved after methylphenidate on the QB Test.
The study of OPTAx and the QB Test share only some results.
This may be explained by the larger sample size in the OPTAx
study, and the fact that all of their participants were evaluated
shortly before the trial regarding both diagnosis and
medication dose.
Some studies focus on RT and RT variability [24]. When
comparing children with ADHD with age-adjusted controls, it is
found that they have longer RT and greater RT variability as a
symptom of decreased overall attention but also a lack of
sustained attention [9,11,23-25].
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QB Test finds a significant improvement of reaction time,
indicating an increased sustained attention (p=0.038).
The variability in reaction time has provided the basis for a
study which indicates that a great RT variability is able to
predict a bad response to methylphenidate [24,25].
In this study, no link between great RT variability and a
lower improvement on the parameters of the three core
symptoms was found when using the QB Test. There is a
possibility that the sample size of this study is too small to
show a connection between insufficient effect of medication
and a certain parameter of the QB Test.
The variant of CPT used in the Region of Southern Denmark
is the QB Test. In this test, the number of correct and non-
correct pressings is not taken into consideration. It is possible
that these two outcomes, in addition to the ones already used,
could shed some light on the effect of medication. In other
studies, a concept known as accuracy is also being used as a
measure of attention [6,10]. Accuracy is measured as the
percentage of correct responses to both targets and non-
targets, but this is not a part of the final analyses of the QB
Test.
The results of this study must be interpreted in the context
of the following limitations. First of all, the size of the sample is
small. This may mean that we do not have the statistical power
to obtain significant results on the QB Test, even if the
participants do in fact have effect of their medication. In a
small sample, it only takes a few participants with outlying
results to blur effect or lack of effect of medication on the core
symptoms of ADHD. In a study with 8 outcomes, the risk of
coincidental results due to multiple comparisons needs to be
considered. With a significance level of 0.05, it is not unlikely
that 1 of our 8 outcomes is false.
In addition, it would have made the setting more accurate if
the participants had had a medication adjustment shortly
before the QB testing.
Furthermore, there was no investigation of the motivation
of the participants. It was obvious that some were very bored
during the QB Test, and this may have caused the results to be
obscured by inattentiveness caused by boredom rather than
lack of medication effect.
It is difficult to imagine an entertaining computer-based
program that does not allow the participants to improve by
repetition, but despite several attempts requires them still to
be willing to make an effort.
The purpose of the study was to investigate the effect of
methylphenidate on QB Test in a group of boys that have
ADHD of varying severity (rated by parents on ADHD-RS) of the
3 core symptoms. The results of this study show that it is
possible to see improvements from methylphenidate on
certain parameters of the QB Test. Overall, there was an
improvement in attentiveness in those most inattentive, and in
activity in those most hyperactive. It was not possible to find
significant improvement in impulsivity on the QB Test.
Thus the study also demonstrates the challenge inherent in
this type of test because the participants had trouble staying
focused on the test for the entire time. This might be
explained by their condition, but it might also be due to the
configuration of the test.
In a clinical view, we do not find that the QB Test can stand
alone in the diagnostic process, evaluation of symptoms or
monitoring effects of medication. The QB Test can, however,
help clarify the existence and/or severity of the core symptoms
of ADHD.
It is important also to look at the data without using the QB
Test program’s interpretation. In this way, it is possible to take
more aspects of attention into consideration. By using the
number of correct responses and correct non-responses in
relation to the total number of responses, it is possible to get a
measure of accuracy.
The illustrative images that the QB Test generates might also
be useful as a tool when teaching parents and/or children.
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